NCT06711887 - Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension) | Biotech Hunter

Enrollment

316

Participants

Timeline

Start Date

May 19, 2025

Primary Completion Date

July 18, 2030

Study Completion Date

July 28, 2032

Conditions

Lupus Nephritis

Interventions

DRUG

Ianalumab

Ianalumab (VAY736) is a human monoclonal antibody (mAb) of the IgG1/κ-class, directed against B cells and binding to BAFF receptor (BAFF-R).

Trial Locations (8)

RECRUITING

Novartis Investigative Site, Bangkok

RECRUITING

Novartis Investigative Site, Suwon

RECRUITING

Novartis Investigative Site, Chiang Mai

RECRUITING

Novartis Investigative Site, Singapore

RECRUITING

Novartis Investigative Site, Binzhou

RECRUITING

Novartis Investigative Site, Guangzhou

RECRUITING

Novartis Investigative Site, Budapest

RECRUITING

Novartis Investigative Site, Seoul